Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer
Abstract Background Sarcopenia is an age-related syndrome that may have negative impact on surgical outcomes and long-term survival of patients with gastric cancer. Serum creatinine/cystatin C (Cr/CysC) ratio has attracted attention as a surrogate marker for sarcopenia but has not been adequately st...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-01-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-022-02093-4 |
| _version_ | 1819260946669895680 |
|---|---|
| author | Jing Sun Hui Yang Wentao Cai Jingwei Zheng Ningzhe Shen Xinxin Yang Bujian Pan Weiteng Zhang Xiaodong Chen Xian Shen |
| author_facet | Jing Sun Hui Yang Wentao Cai Jingwei Zheng Ningzhe Shen Xinxin Yang Bujian Pan Weiteng Zhang Xiaodong Chen Xian Shen |
| author_sort | Jing Sun |
| collection | DOAJ |
| description | Abstract Background Sarcopenia is an age-related syndrome that may have negative impact on surgical outcomes and long-term survival of patients with gastric cancer. Serum creatinine/cystatin C (Cr/CysC) ratio has attracted attention as a surrogate marker for sarcopenia but has not been adequately studied in patients with gastric cancer. The purpose of this study was to investigate the validity of serum Cr/CysC ratio as a predictor of sarcopenia, evaluate a statistical cut-off value, and assess the relationship between Cr/CysC ratio and prognosis of patients with gastric cancer. Methods We retrospectively studied 327 patients who underwent surgery for gastric cancer from June 2009 to October 2021. The skeletal muscle mass index was calculated using computed tomography (CT). We determined the relevance of serum Cr/CysC ratio as a surrogate maker for sarcopenia by comparing it with various biomarkers. The Concordance index (C-index) was calculted to measure whether the Cr/CysC ratio can prognosis of patients with gastric cancer. Results Serum Cr/CysC was significantly correlated with with Skeletal Muscle Index (SMI) (r = 0.221, p < 0.001) and Skeletal Muscle Area (SMA) (r = 0.258, p < 0.001). The area under the curve for sarcopenia was significantly larger for serum Cr/CysC ratio than for other biomarkers (Cr/CysC: 0.644, CysC: 0.535, Cr: 0.556). Patients in the high-Cr/CysC group have longer survival time than that in low-Cr/CysC group, defined by the cutoff value 0.67. The C-index of both Cr/CysC ratio and SMI with OS was 0.63. Conclusions Serum Cr/CysC ratio can be used accurately, inexpensively, and easily to evaluate sarcopenia in male patients with gastric cancer. Our study shows that patients with Cr/CysC below 0.67 had possibility of sarcopenia and would be poor prognosis. |
| first_indexed | 2024-12-23T19:33:59Z |
| format | Article |
| id | doaj.art-cf25f690a9234212a312ce882e6ea54d |
| institution | Directory Open Access Journal |
| issn | 1471-230X |
| language | English |
| last_indexed | 2024-12-23T19:33:59Z |
| publishDate | 2022-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj.art-cf25f690a9234212a312ce882e6ea54d2022-12-21T17:33:50ZengBMCBMC Gastroenterology1471-230X2022-01-012211910.1186/s12876-022-02093-4Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancerJing Sun0Hui Yang1Wentao Cai2Jingwei Zheng3Ningzhe Shen4Xinxin Yang5Bujian Pan6Weiteng Zhang7Xiaodong Chen8Xian Shen9Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Wenzhou Medical UniversityDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital, Wenzhou Medical UniversityDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital, Wenzhou Medical UniversityDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital, Wenzhou Medical UniversityDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital, Wenzhou Medical UniversityDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital, Wenzhou Medical UniversityDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital, Wenzhou Medical UniversityDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital, Wenzhou Medical UniversityDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital, Wenzhou Medical UniversityDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital, Wenzhou Medical UniversityAbstract Background Sarcopenia is an age-related syndrome that may have negative impact on surgical outcomes and long-term survival of patients with gastric cancer. Serum creatinine/cystatin C (Cr/CysC) ratio has attracted attention as a surrogate marker for sarcopenia but has not been adequately studied in patients with gastric cancer. The purpose of this study was to investigate the validity of serum Cr/CysC ratio as a predictor of sarcopenia, evaluate a statistical cut-off value, and assess the relationship between Cr/CysC ratio and prognosis of patients with gastric cancer. Methods We retrospectively studied 327 patients who underwent surgery for gastric cancer from June 2009 to October 2021. The skeletal muscle mass index was calculated using computed tomography (CT). We determined the relevance of serum Cr/CysC ratio as a surrogate maker for sarcopenia by comparing it with various biomarkers. The Concordance index (C-index) was calculted to measure whether the Cr/CysC ratio can prognosis of patients with gastric cancer. Results Serum Cr/CysC was significantly correlated with with Skeletal Muscle Index (SMI) (r = 0.221, p < 0.001) and Skeletal Muscle Area (SMA) (r = 0.258, p < 0.001). The area under the curve for sarcopenia was significantly larger for serum Cr/CysC ratio than for other biomarkers (Cr/CysC: 0.644, CysC: 0.535, Cr: 0.556). Patients in the high-Cr/CysC group have longer survival time than that in low-Cr/CysC group, defined by the cutoff value 0.67. The C-index of both Cr/CysC ratio and SMI with OS was 0.63. Conclusions Serum Cr/CysC ratio can be used accurately, inexpensively, and easily to evaluate sarcopenia in male patients with gastric cancer. Our study shows that patients with Cr/CysC below 0.67 had possibility of sarcopenia and would be poor prognosis.https://doi.org/10.1186/s12876-022-02093-4Serum Cr/CysC ratioSarcopeniaGastric cancer |
| spellingShingle | Jing Sun Hui Yang Wentao Cai Jingwei Zheng Ningzhe Shen Xinxin Yang Bujian Pan Weiteng Zhang Xiaodong Chen Xian Shen Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer BMC Gastroenterology Serum Cr/CysC ratio Sarcopenia Gastric cancer |
| title | Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer |
| title_full | Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer |
| title_fullStr | Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer |
| title_full_unstemmed | Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer |
| title_short | Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer |
| title_sort | serum creatinine cystatin c ratio as a surrogate marker for sarcopenia in patients with gastric cancer |
| topic | Serum Cr/CysC ratio Sarcopenia Gastric cancer |
| url | https://doi.org/10.1186/s12876-022-02093-4 |
| work_keys_str_mv | AT jingsun serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT huiyang serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT wentaocai serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT jingweizheng serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT ningzheshen serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT xinxinyang serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT bujianpan serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT weitengzhang serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT xiaodongchen serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT xianshen serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer |